Nanobiotix reports phase 2 data as JNJ-1900 posts 85.7% response in NSCLC

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Nanobiotix flagged Part 1 results from Johnson & Johnson’s randomized Phase 2 CONVERGE trial of JNJ-1900 (NBTXR3) in stage III inoperable non-small cell lung cancer, already presented at ESTRO 2026.
  • Early findings showed the intratumoral or intranodal injection approach was feasible, with no new safety concerns highlighted.
  • Investigators reported encouraging tumor shrinkage signals in the first patients who completed the full regimen, with deep responses that compared favorably with typical outcomes for current standard care.
  • The absence of disease progression in the treated group, alongside responses that strengthened over time, supported the case for further development and potential durability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605171015OMX_____CNEWS_EN_GNW9721388_en) on May 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.